GB2478931B - Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity - Google Patents

Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity

Info

Publication number: GB2478931B
Authority: GB; United Kingdom
Prior art keywords: caffeine; aspirin; improving performance; sporting activity; synergistic amounts
Prior art date: 2010-03-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

GB1004831.2A

Other versions

GB201004831D0 (en

GB2478931A (en

Inventor

John Paul Kelly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-23

Filing date

2010-03-23

Publication date

2013-06-12

2010-03-23 Application filed by Individual filed Critical Individual

2010-03-23 Priority to GB1004831.2A priority Critical patent/GB2478931B/en

2010-05-05 Publication of GB201004831D0 publication Critical patent/GB201004831D0/en

2011-03-23 Priority to PCT/EP2011/054496 priority patent/WO2011117322A2/en

2011-09-28 Publication of GB2478931A publication Critical patent/GB2478931A/en

2013-06-12 Application granted granted Critical

2013-06-12 Publication of GB2478931B publication Critical patent/GB2478931B/en

Status Active legal-status Critical Current

2030-03-23 Anticipated expiration legal-status Critical

Links

RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title 1
229960001138 acetylsalicylic acid Drugs 0.000 title 1
229960001948 caffeine Drugs 0.000 title 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000002195 synergetic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

GB1004831.2A 2010-03-23 2010-03-23 Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity Active GB2478931B (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GB1004831.2A GB2478931B (en)	2010-03-23	2010-03-23	Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity
PCT/EP2011/054496 WO2011117322A2 (en)	2010-03-23	2011-03-23	Use of caffeine and aspirin in synergistic amounts for improving performance

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB1004831.2A GB2478931B (en)	2010-03-23	2010-03-23	Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity

Publications (3)

Publication Number	Publication Date
GB201004831D0 GB201004831D0 (en)	2010-05-05
GB2478931A GB2478931A (en)	2011-09-28
GB2478931B true GB2478931B (en)	2013-06-12

Family

ID=42228176

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB1004831.2A Active GB2478931B (en)	2010-03-23	2010-03-23	Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity

Country Status (2)

Country	Link
GB (1)	GB2478931B (en)
WO (1)	WO2011117322A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1137379A (en) *	1912-12-21	1915-04-27	Alfred W Beuttell	Show-case light.
US5055460A (en) *	1990-04-26	1991-10-08	Mitchell Friedlander	Method for weight loss
WO1999003475A1 (en) *	1997-07-14	1999-01-28	Bristol-Myers Squibb Company	Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
US7078052B2 (en) *	1999-04-06	2006-07-18	Wm. Wrigley Jr. Company	Pharmaceutical chewing gum formulations
WO2007001957A1 (en) *	2005-06-24	2007-01-04	Soluprin Pharmaceuticals, Inc.	Water soluble analgesic formulations and methods for production
WO2007056176A2 (en) *	2005-11-03	2007-05-18	Southwest Immunology, Inc.	Compositions for preventing and reducing delayed onset muscle soreness

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1986003681A1 (en) *	1984-12-26	1986-07-03	Abraham Sunshine	Analgesic, anti-inflammatory and skeletal muscle relaxant compositions

2010
- 2010-03-23 GB GB1004831.2A patent/GB2478931B/en active Active
2011
- 2011-03-23 WO PCT/EP2011/054496 patent/WO2011117322A2/en active Application Filing

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1137379A (en) *	1912-12-21	1915-04-27	Alfred W Beuttell	Show-case light.
US5055460A (en) *	1990-04-26	1991-10-08	Mitchell Friedlander	Method for weight loss
WO1999003475A1 (en) *	1997-07-14	1999-01-28	Bristol-Myers Squibb Company	Use of compositions containing the combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
US7078052B2 (en) *	1999-04-06	2006-07-18	Wm. Wrigley Jr. Company	Pharmaceutical chewing gum formulations
WO2007001957A1 (en) *	2005-06-24	2007-01-04	Soluprin Pharmaceuticals, Inc.	Water soluble analgesic formulations and methods for production
WO2007056176A2 (en) *	2005-11-03	2007-05-18	Southwest Immunology, Inc.	Compositions for preventing and reducing delayed onset muscle soreness

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"A double-blind randomized study of an aspirin/caffeine combination versus acetaminophen/aspirin combination versus acetaminophen versus placebo in patients with moderate to severe post-partum pain", A. Rubin & L. Winter, J. Int. Med. Res. (1984), 12, 338-345 *
"How does ripped fuel work ?", A.J. Medina, Internet article dated 12 September 2009 - found at the following URL; http://www.livestrong.com/article/32157-ripped-fuel-work *
"The effects of caffeine and aspirin on mood and performance", H.R. Lieberman et al, J. Clin. Psychopharmacology, (1987), 7(5), 315-320 *
Drug abuse in sports, Utah poison control centre, Internet article dated 1st Jan 2002 found at the following URL; http://uuhsc.utah.edu/poison/healthpros/utox/vol4_no1.pdf *

Also Published As

Publication number	Publication date
WO2011117322A3 (en)	2012-01-12
GB201004831D0 (en)	2010-05-05
WO2011117322A2 (en)	2011-09-29
GB2478931A (en)	2011-09-28

Publication	Publication Date	Title
EP2765881A4 (en)	2015-04-22	Welt-frame construction and protection devices for use in shoes
EP2691884A4 (en)	2015-06-03	Management and storage of distributed bookmarks
ZA201303587B (en)	2014-04-30	Performance enhancing sports beverage and methods of use
HK1200029A1 (en)	2015-07-31	Nadph oxidase 4 inhibitors and use thereof nadph 4
HK1195736A1 (en)	2014-11-21	Radioimmunoconjugates and their use
HK1204892A1 (en)	2015-12-11	Improvements in and relating to cushions
GB201120993D0 (en)	2012-01-18	Novel compounds and their use in therapy
HK1199378A1 (en)	2015-07-03	Compositions and methods for use in promoting lean body mass
AP2013007331A0 (en)	2013-12-31	TRPM8 antagonists and their use in treatments
EP2523689A4 (en)	2013-09-11	Il-22-fc and hepcidin activity
HK1198122A1 (en)	2015-03-13	Eosinophil peroxidase compositions and methods of their use
EP2603221A4 (en)	2014-02-26	Ggf2 and methods of use
EP2817304A4 (en)	2015-01-21	Novel compounds and their use in therapy
EP2762129A4 (en)	2015-07-01	Cosmetic composition and cosmetic
EP2744478A4 (en)	2015-07-29	Marine based cosmetic active ingredients and use thereof
EP2697386A4 (en)	2014-12-03	Pepducin design and use
GB201004936D0 (en)	2010-05-12	Improvements in and relating to furniture
PT2590509T (en)	2019-02-06	Method for the preparation and the use of biocides enriched in active radicals before usage
EP2534258A4 (en)	2014-02-05	Dual activity kinase domains and uses thereof
EP2877194A4 (en)	2016-03-16	Compositions and methods for increasing carnitine level in muscle tissues
EP2683386A4 (en)	2014-07-30	Compounds and methods of use in ablative radiotherapy
GB2478931B (en)	2013-06-12	Use of caffeine and aspirin in synergistic amounts for improving performance in sporting activity
GB201218050D0 (en)	2012-11-21	Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome
GB2495390B (en)	2018-09-26	Improvements in and relating to construction
EP2723349A4 (en)	2015-01-14	Microrna-31 compositions and methods for use in autoimmune disease